Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 17, Issue 5, Pages 643-655
Publisher
Informa Healthcare
Online
2015-12-03
DOI
10.1517/14656566.2016.1127353
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study
- (2015) Lothar Bergmann et al. BMC CANCER
- Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor
- (2015) Inkeun Park et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center
- (2015) Sonia Vallet et al. Clinical Genitourinary Cancer
- A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
- (2015) Laurence Albiges et al. EUROPEAN UROLOGY
- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
- (2015) Christian Eichelberg et al. EUROPEAN UROLOGY
- EAU Guidelines on Renal Cell Carcinoma: 2014 Update
- (2015) Borje Ljungberg et al. EUROPEAN UROLOGY
- Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity
- (2015) Camillo Porta et al. Future Oncology
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors in Patients Receiving Third Line Targeted Therapy for Metastatic Renal Cell Carcinoma
- (2015) Roberto Iacovelli et al. JOURNAL OF UROLOGY
- Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile
- (2015) Sumanta Kumar Pal et al. JOURNAL OF UROLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
- (2014) R. Elaidi et al. ANNALS OF ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) B. Escudier et al. ANNALS OF ONCOLOGY
- Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
- (2014) B Escudier et al. BRITISH JOURNAL OF CANCER
- Sunitinib re-challenge in advanced renal-cell carcinoma
- (2014) C Porta et al. BRITISH JOURNAL OF CANCER
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2014) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis11T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).
- (2014) Tomas Buchler et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- GOAL: An inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer
- (2013) Sergio Bracarda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort
- (2013) Roberto Iacovelli et al. EUROPEAN JOURNAL OF CANCER
- The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma
- (2013) F Stenner-Liewen et al. Expert Review of Anticancer Therapy
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
- (2013) Nicola Calvani et al. MEDICAL ONCOLOGY
- Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors
- (2013) Masafumi Kumano et al. MEDICAL ONCOLOGY
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy
- (2013) Agnes Maj-Hes et al. ONCOLOGY
- The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients
- (2013) Mhd Y. Al-Marrawi et al. Targeted Oncology
- SORAFENIB RECHALENGE IN METASTATIC RENAL CELL CARCINOMA
- (2012) Camillo Porta et al. BJU INTERNATIONAL
- Sorafenib rechallenge in patients with metastatic renal cell carcinoma
- (2012) Masahiro Nozawa et al. BJU INTERNATIONAL
- Second-Line Therapy After VEGF Targeted Therapy in Metastatic Renal Cancer: A Law of Diminishing Returns
- (2012) Thomas Powles Clinical Genitourinary Cancer
- Retrospective Comparison of Triple-sequence Therapies in Metastatic Renal Cell Carcinoma
- (2012) Jonas Busch et al. EUROPEAN UROLOGY
- Treatment selection in metastatic renal cell carcinoma: expert consensus
- (2012) Bernard Escudier et al. Nature Reviews Clinical Oncology
- A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
- (2012) Frank Stenner et al. ONCOLOGY
- Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
- (2011) D. Y. Heng et al. ANNALS OF ONCOLOGY
- Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
- (2011) E. Calvo et al. EUROPEAN JOURNAL OF CANCER
- Entropy Increases in Kidney Cancer Treatment, but a Bit of Simplicity May Emerge From Chaos
- (2011) Camillo Porta EUROPEAN UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Efficacy of Sunitinib Re-Exposure after Failure of an mTOR Inhibitor in Patients with Metastatic RCC
- (2011) Viktor Grünwald et al. ONKOLOGIE
- Sunitinib rechallenge in metastatic renal cell carcinoma patients
- (2010) Ivan N. Zama et al. CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- (2010) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma
- (2009) Camillo Porta et al. CANCER TREATMENT REVIEWS
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started